New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:23 EDTTKMR, MONTekmira signs license option agreement with Monsanto
Tekmira Pharmaceuticals (TKMR) announced that it has signed an Option Agreement with Monsanto (MON), pursuant to which Monsanto may obtain a license to use Tekmira's proprietary delivery technology. The transaction will support the application of Tekmira's proprietary delivery technology and related intellectual property for use in agriculture. Tekmira noted that the potential value of the transaction could reach up to $86.2M following the successful completion of milestones. Tekmira expects to receive a near term payment of net $16.5M. Over the option period, which is expected to be approximately four years, Tekmira will provide lipid formulations to Monsanto's research and development activities, and Monsanto will make certain payments to Tekmira to maintain its option rights. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto will pay to Tekmira an option exercise fee and will receive a worldwide, exclusive right to use Tekmira's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. Tekmira retains all rights to therapeutics uses of all current IP and IP developed under the agreement. The agreement follows Monsanto's initial testing of Tekmira's proprietary delivery technology and the demonstration of initial positive results from use of that technology in the field of agriculture, the company said.
News For TKMR;MON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 19, 2014
13:39 EDTTKMRCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTTKMRBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTTKMRSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 16, 2014
14:13 EDTMONU.S farmers use less fertilizer this autumn as crop prices fade, Reuters says
Subscribe for More Information
October 15, 2014
15:34 EDTTKMRTekmira TKM-HBN preclinical study shows 'knockdown of HBV surface antigen'
Subscribe for More Information
10:49 EDTTKMREbola linked names rise again amid broader market sell-off
Subscribe for More Information
09:57 EDTTKMRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:58 EDTTKMRTekmira volatility up, 2nd Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 14, 2014
11:19 EDTTKMRNIH says several potential Ebola treatments under development
Subscribe for More Information
10:10 EDTTKMRNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
09:04 EDTTKMRChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
05:40 EDTTKMRTekmira partner Alnylam reports positive clinical data for Patisiran study
Tekmira Pharmaceuticals (TKMR) reported that Alnylam Pharmaceuticals (ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension, or OLE, study in patients with Familial Amyloidotic Polyneuropathy, or FAP. Patisiran is an RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, which is enabled by Tekmira's lipid nanoparticle, or LNP, technology. Alnylam presented data at the American Neurological Association's 2014 Annual Meeting. Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score at six months in 19 patients with mNIS+7 data available for the current analysis. This decrease in neuropathy progression compares favorably with the 7 to 10 point increase in mNIS+7 at six months that can be estimated from historical data sets in untreated FAP patients with similar baseline characteristics.
October 13, 2014
07:45 EDTMONU.S. chemical company declines an overreaction to macro outlook, says UBS
Subscribe for More Information
07:12 EDTTKMROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
07:11 EDTTKMRTekmira volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 12, 2014
19:26 EDTTKMRPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTTKMRCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
17:20 EDTMONGE, Splunk, Cisco, others could benefit from Internet of Things, Barron's says
Subscribe for More Information
14:18 EDTTKMRNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTTKMRTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use